The Treatment of Herpes Simplex Infections

An Evidence-Based Review

Christina Cernik, MD; Kelly Gallina, MD; Robert T. Brodell, MD

Genital and labial herpes simplex virus infections are frequently encountered by primary care physicians in the United States. Whereas the diagnosis of this condition is often straightforward, choosing an appropriate drug (eg, acyclovir, valacyclovir hydrochloride, or famciclovir) and dosing regimen can be confusing in view of (1) competing clinical approaches to therapy; (2) evolving dosing schedules based on new research; (3) approved regimens of the Food and Drug Administration that may not match recommendations of the Centers for Disease Control and Prevention or of other experts; and (4) dissimilar regimens for oral and genital infections. The physician must first choose an approach to treatment (ie, intermittent episodic therapy, intermittent suppressive therapy, or chronic suppressive therapy) based on defined clinical characteristics and patient preference. Then, an evidence-based dosing regimen must be selected. In this review, data from all sources are tabulated to provide a handy clinical reference.

Acyclovir, valacyclovir hydrochloride, and famciclovir are the 3 antiviral drugs routinely used to treat symptomatic herpes simplex virus (HSV) infections. Diagnosing HSV infections is usually straightforward in immunocompetent patients, and all the available drugs have an excellent margin of safety because they are converted by viral thymidine kinase to the active drug only inside virally infected cells. Unfortunately, confusion often arises because various dosing regimens are recommended for (1) each of the 3 available drugs; (2) HSV vs herpes zoster; (3) suppressive vs intermittent episodic indications; (4) primary vs secondary infections; (5) oral and genital infections; and (6) evolving treatment strategies approved by the Food and Drug Administration. Following a literature review to document important clinical information about HSV infections, we discuss the data regarding optimal treatment regimens. Three approaches to treatment are described: intermittent episodic therapy (IET), chronic suppressive therapy (CST), and intermittent suppressive therapy (IST).

An outbreak of genital or labial herpes is categorized as a primary HSV infection if the patient was seronegative for HSV types 1 and 2 before the episode and as a nonprimary HSV infection if previous infections had occurred. Without acquired immunity, initial primary infections are generally more severe than recurrences. Constitutional symptoms such as fever, chills, fatigue, and muscle aches accompany the disease and last 10 to 14 days. A first episode of genital or oral herpes in a patient already seropositive for HSV is termed a nonprimary initial infection, and these infections tend to be less severe. The disease course after initial infection is variable; some patients have recurrent infections, and others never experience a second episode.

Labial herpes typically results from infection with HSV type 1 and is commonly contracted during childhood or adolescence. In the US, 57% to 80% of
of involvement in women, yet the classic clinical picture is that of painful and disfiguring vaginal and vulvar lesions.15 Men typically develop lesions on the glans, prepuce, or shaft of the penis. The natural course of disease progression is decreased frequency and severity of recurrences over time. However, roughly a third of patients do not experience this time-dependent regression.17

Herpes zoster and other blistering diseases can mimic HSV infections. The diagnosis of herpes infections can be confirmed immediately by Tzanck preparation, within hours using immunofluorescence techniques, and within 48 hours using viral culture.

The clinical courses of genital herpes caused by HSV types 1 and 2 are indistinguishable. There is typically a 2- to 21-day incubation period following viral inoculation when randomly distributed vesicles clustered on a red base appear. Tiny papules develop into vesicles, which subsequently ulcerate and crust.18 Soreness, itching, dysuria, and inguinal or femoral lymphadenopathy may accompany constitutional symptoms, and dysuria is common in women.18,19 Untreated eruptions of genital herpes typically last longer than those of the oral variety, with a primary episode enduring for 2 to 4 weeks. Recurrent genital herpes produces localized vesicles on an erythematous base, which persist for 7 to 12 days without treatment.10,11

Table 1. Episodic Dosing for Initial Primary Labial Herpes

<table>
<thead>
<tr>
<th>Antiviral Drug</th>
<th>Dosing Schedule</th>
<th>Level of Evidence</th>
<th>FDA Approved</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acyclovir</td>
<td>15 mg/kg 5 times a day for 7 d</td>
<td>I</td>
<td>No</td>
</tr>
<tr>
<td>Valacyclovir hydrochloride</td>
<td>1 g twice a day for 7 d</td>
<td>II</td>
<td>No</td>
</tr>
<tr>
<td>Famciclovir</td>
<td>500 mg twice a day for 7 d</td>
<td>II</td>
<td>No</td>
</tr>
</tbody>
</table>

Abbreviation: FDA, Food and Drug Administration.

Initial Primary Infections. In moderate and severe cases, antiviral treatment is often recommended for uncomplicated episodes of primary oral herpes in healthy patients (Table 1).7 Oral acyclovir suspension, 15 mg/kg 5 times daily for 1 week, significantly decreased the disease duration and the period of infectivity in children in a small RCT. Median duration of oral lesions was 4 days vs 9 days for the placebo group, and median time to negative viral cultures was 1 day vs 5 days.21 Valacyclovir hydrochloride, 1 g twice a day for 7 days, and famciclovir, 300 mg twice a day or once a day for 7 days, are also logical regimens, although RCTs have not been performed.3,22 Treatment is most effective when initiated promptly. However, early treatment does not appear to diminish recurrences.

Recurrent Infections. The intermittent use of an oral antiviral agent is effective in the treatment of recurrent labial herpes when initiated within 48 hours of an outbreak (Table 2). Randomized controlled trials have shown systemic acyclovir (400 mg 5 times daily for 5 days) decreases healing time and viral shedding and ameliorates symptoms when initiated early.11,23 Valacyclovir, the prodrug of acyclovir, provides a 3- to 5-fold increase in bioavailability of acyclovir.24 Two large RCTs demonstrated that single-day administration of valacyclovir...
(2 g given twice in 24 hours) significantly reduces episode duration, time to lesion healing, and time to cessation of pain and discomfort when compared with placebo. A 1-day reduction in lesion duration was documented.

Famciclovir, the oral prodrug of penciclovir, offers increased bioavailability as well as a substantially longer half-life compared with acyclovir. In an RCT, famciclovir, given as either a single 1500-mg dose or as two 750-mg doses during a 24-hour period, decreased healing time and provided symptomatic relief. Time to lesion healing and normal reepithelialization was 2 days shorter and symptom resolution was 1 day faster when compared with the control group.10,25

Intermittent episodic therapy with topical acyclovir and penciclovir creams have been shown to decrease lesion healing time and symptom severity in recurrent labial herpes.11,26,27,29-32 Other studies, however, failed to prove acyclovir ointment and cream efficacious.33,34 Overall, topical treatments do not appear to be as effective as systemic medications. For instance, famciclovir decreases lesion healing time by 2 days, efficacy that has not been demonstrated with topical therapy.10,26,35-37

IET in Genital Herpes Simplex

Initial Primary Infections. Patients with primary episodes of genital herpes are effectively treated with antiviral drugs when taken within 72 hours of lesion appearance (Table 3). Oral and intravenous acyclovir have been used to shorten the course of primary genital herpes infections for decades. Unlike topical acyclovir, the oral form can prevent new lesion formation and modify accompanying constitutional symptoms, and does not cause local irritation on application.38 Oral acyclovir is more practical than the intravenous route for immunocompetent patients.38 Acyclovir (1 g to 1200 mg/d) produces results matching those of higher dosages (4 g/d). Neither regimen appears to affect the frequency or course of future genital herpes recurrences.39

Head-to-head trials comparing 10-day regimens of oral acyclovir (200 mg 5 times daily) and valacyclovir (1000 mg twice a day) found no statistically significant difference between the 2 in terms of disease outcome measures.40 However, valacyclovir, when taken once or twice daily, is likely to increase compliance compared with acyclovir, which is taken 5 times a day.40

Similarly, an RCT comparing the efficacy of 5- and 10-day regimens of several famciclovir dosages (250 mg, 500 mg, or 750 mg 3 times a day for 5 days and 125 mg, 250 mg, or 500 mg 3 times a day for 10 days) with acyclovir (200 mg 5 times a day for 5 or 10 days) in first-episode genital herpes cases found no significant differences between the two drugs. Duration of viral shedding, median time to lesion healing, and time to symptom resolution were comparable between both treatment groups.42,43 The 10-day treatment arm of the study demonstrated that higher doses of famciclovir (250 mg and 500 mg) were superior to the 125-mg regimen. The Centers for Disease Control and Prevention has chosen to recommend the 10-day dosing schedule, although the 5 and 10-day regimens of famciclovir (250 mg 3 times a day and all 500-mg groups) demonstrated comparable efficacy.42,43 Famciclovir 3 times a day should enhance compliance when compared with the 5 times daily dosage of acyclovir.

Recurrent Infections. In the 1980s, oral acyclovir (200 mg 5 times daily for 5 days) was found to significantly decrease viral shedding, hasten lesion healing, and decrease the incidence of new lesion formation.41,44 It was also associated with a truncated course of pain and discomfort, but had no effect on recurrences.41,45 Abbreviated courses using higher dosages of acyclovir, 800 mg twice a day for 5 days and 3 times a day for 2 days, have proven to be as effective as earlier regimens.46,47 Moreover, the higher dosage was effective in healing established lesions in men, even when initiated after the prodromal period.46

Oral valacyclovir (500 mg twice a day for 5 days and 1 g once a day for 5 days) has been shown in placebo-controlled and head-to-head studies to match acyclovir in terms of decreasing episode length, viral shedding, and healing time.45,46 The 3-day valacyclovir regimen (500 mg twice a day) was shown to be as effective as 5 days of treatment.49 Multiple studies have also demonstrated that valacyclovir significantly

<table>
<thead>
<tr>
<th>Table 2. Intermittent Episodic Therapy or Recurrent Labial Herpes</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antiviral Drug</strong></td>
</tr>
<tr>
<td>-------------------</td>
</tr>
<tr>
<td>Acyclovir</td>
</tr>
<tr>
<td>Valacyclovir hydrochloride</td>
</tr>
<tr>
<td>Famiclovir</td>
</tr>
<tr>
<td>Topical therapy</td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

Abbreviation: FDA, Food and Drug Administration.

<table>
<thead>
<tr>
<th>Table 3. Episodic Dosing for Initial Primary Genital Herpes</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antiviral Drug</strong></td>
</tr>
<tr>
<td>-------------------</td>
</tr>
<tr>
<td>Acyclovir</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Valacyclovir hydrochloride</td>
</tr>
<tr>
<td>Famiclovir</td>
</tr>
</tbody>
</table>

Abbreviations: CDC, Centers for Disease Control and Prevention; FDA, Food and Drug Administration.
Table 4. Intermittent Episodic Therapy for Recurrent Genital Herpes

<table>
<thead>
<tr>
<th>Antiviral Drug</th>
<th>Dosing Schedule</th>
<th>Level of Evidence</th>
<th>FDA Approved</th>
<th>CDC Recommended</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acyclovir</td>
<td>200 mg 5 times a day for 5-10 d</td>
<td>41,42,43,44,45,46,47,48,49,50,51,52,53 No Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Valacyclovir hydrochloride</td>
<td>500 mg twice a day for 3 d</td>
<td>47,48,49,50,51,52,53 No Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Famiclovir</td>
<td>125 mg twice a day for 5 d</td>
<td>46,47,48,49,50,51,52,53 Yes (7-d regimen)</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td></td>
<td>500 mg twice a day for 5-10 d</td>
<td>46,47,48,49,50,51,52,53 Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
</tbody>
</table>

Abbreviations: CDC, Centers for Disease Control and Prevention; FDA, Food and Drug Administration.

For human immunodeficiency virus–positive patients, suggested regimens were derived from studies of patients with genital herpes. However, we expect these treatments to also be useful for patients with labial herpes.

decreases the duration and severity of pain and discomfort associated with genital herpes episodes. There is conflicting evidence regarding the ability of valacyclovir to abort outbreaks when taken at the onset of symptoms before any lesions are apparent. Data trends and our clinical experience suggest that at least some recurrences can be aborted through this approach.

In addition, varying dosages of famciclovir (125 mg, 250 mg, or 500 mg twice a day for 5 days) significantly affect the characteristics mentioned previously. No dose-dependent advantages exist between regimens. Therefore, the lowest dosage of 125 mg twice a day is recommended. Viral shedding is decreased by 1 1/2 days and roughly leads to complete lesion healing 1 day faster than placebo. There is a 50% absolute risk reduction of developing new lesions compared with placebo, and the treatment group enjoyed at least a half-day reduction in lesion-associated pain and discomfort. A single-day, 2-dose regimen demonstrated a 2-day reduction in median time to healing and overall efficacy equal to that of multiple day, lower-dose famciclovir regimens. Table 4 summarizes these data.

The efficacy of topical acyclovir cream used as treatment in primary or recurrent episodes of genital herpes varies between RCTs and overall does not appear to be as reliable as oral acyclovir. Current Centers for Disease Control and Prevention guidelines discourage the use of the topical formulations, stating that they offer “minimal clinical benefit.”

CHRONIC SUPPRESSIVE THERAPY

Although most patients with HSV infections do not require CST, those with frequent recurrences who experience severe pain or disfigurement, have difficulty swallowing, or experience a protracted disease course are appropriately treated with CST. Of all patients with labial herpes, 5% to 10% experience frequent recurrences (≥6 per year). Of patients infected with genital herpes, 20% to 50% have symptomatic, recurrent flares. Patients have a median of 4 recurrences the year after a first symptomatic episode and usually enjoy a decline in frequency of outbreaks over time. Recurrences of any frequency can negatively affect a patient’s quality of life. Thus, CST is appropriate for patients who are psychologically distressed by their disease. Long-term prophylactic therapy for genital herpes may also be used in an attempt to decrease the risk of transmission to uninfected partners.

CST in Genital Herpes Simplex

Acyclovir was the first drug extensively studied and proven to markedly reduce genital herpes recurrences when taken daily for long periods in the immunocompetent population. A small trial in 1984 found that daily acyclovir (200 mg 3 times a day) taken for 125 days significantly decreased the number of genital herpes recurrences. All patients in the placebo group and 25% of subjects in the treatment group experienced at least 1 recurrence during a 4-month period.
RCTs have shown significant ad-

ing recurrence free (40%, 48%, 50%,

and 49%, respectively) after 1 year.

All these regimens were superior to

placebo. The following years of the trial demonstrated a "gradual and additional

improvement" in response to therapy, with

about 70% of patients remaining rec-

urrence free during the fifth year of

the trial. Overall, studies suggest that acyclovir given as CST for 1 year allows 43% to 50% of pa-

tients to remain recurrence free, with a median time to first recurrence ranging from 246 to 274 days. When control was not achieved at lower doses, most initial nonre-

sponders were controlled with in-

creased doses ranging from 1000 to

1600 mg/d.

Unfortunately, once suppressive

therapy is discontinued, outbreaks of-

ten recur. When discontinued within a year, episodes recur at a frequency comparable to subjects' baselines before chronic prophylactic therapy was ini-

tiated. Of note, a prolonged treat-

ment schedule of 5 years was shown in one study to lower recurrence rates relative to previous baseline in about two-thirds of patients. To date, no RCTs have shown significant ad-

verse effects related to prolonged treat-

ment.

The first RCT conducted on vala-

cyclovir (500 mg once a day), a large

16-week study, demonstrated a sig-

nificant reduction in recurrences (69% vs 9.5% recurrence free) and a significant increase in median time to first recurrence (>112 vs 20 days) in the treatment group compared with the placebo group. Another study evaluating daily single-

dose regimens (250 mg, 500 mg, and

1 g), 250 mg twice a day, 400 mg twice a day, and placebo found 500 mg once a day, 1 g once a day, 250 mg twice a day, and 400 mg twice a day of similar efficacy with regard to the percentage of patients remaining recurrence free (40%, 48%, 50%, and 49%, respectively) after 1 year. All these regimens were superior to

the 250 mg once a day dosage (22% recurrence free) and placebo (5%). More complete suppres-

sion was attained in patients with baseline disease activity of less than 10 recurrences per year, with the 500 mg once a day dosage typically suf-

ficient for control. Patients with 10 or more recurrences per year often needed twice-daily dosing or 1 g once a day for adequate control. Famciclovir has also been proven effective as CST for genital herpes, demonstrating best efficacy when taken multiple times per day. A study conducted only in women evaluated multiple famciclovir dosages (125 mg once or twice daily, 250 mg once or twice daily, and 500 mg once a day) and found the famciclovir dosage of 250 mg twice a day to be the most ef-

fective regimen in significantly pro-

longing time to first clinically and vi-

rally confirmed recurrence. Once-

daily dosing schedules were less effective or provided no significant benefit. A larger study evaluating 250 mg of famciclovir twice a day demonstrated that 70% of those receiving the drug were recurrence free for 1 year, compared with only 20% of patients in the placebo group. Various regimens of the drug (125 mg

3 times a day, 250 mg 3 times a day, and 250 mg twice a day) significantly increase time to first recur-

rence and percentage of patients remaining recurrence free for 1 year. Results attained with 250 mg of famciclovir twice a day or 3 times a day have been similar. Thus, the twice-daily dosing schedule has been suggested to provide a "conve-

nient, effective, and well-tolerated regimen." The length of CST has not been de-

fined by the Food and Drug Admin-

istration and is patient- and disease-

course dependent. Suppression for a year or longer is appropriate in many patients with frequent recurrences. Patients with herpes-associated erythema multiforme, eczema herpeticum (Kaposi varicel-

iform eruption), and herpetic kerato-

titis, and immunocompromised popu-

lations, including human immuno-

deficiency virus–positive individuals, may require indefinite suppressive therapy. Acyclovir resistance occasionally occurs in immuno-

compromised patients. A recent meta-

analysis was performed to elucidate the best CST regimens for genital herpes (Table 6).

### Table 5. Chronic Suppressive Therapy for Labial Herpes

<table>
<thead>
<tr>
<th>Antiviral Drug</th>
<th>Dosing Schedule</th>
<th>Level of Evidence</th>
<th>FDA Approved</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acyclovir</td>
<td>400 mg twice a day</td>
<td>I²</td>
<td>No</td>
</tr>
<tr>
<td>Valacyclovir hydrochloride</td>
<td>500 mg once a day</td>
<td>I²</td>
<td>No</td>
</tr>
<tr>
<td>Famciclovir</td>
<td>500 mg twice a day</td>
<td>V¹</td>
<td>No</td>
</tr>
</tbody>
</table>

Abbreviation: FDA, Food and Drug Administration.

<table>
<thead>
<tr>
<th>Antiviral Drug</th>
<th>Dosing Schedule</th>
<th>Level of Evidence</th>
<th>CDC Approved</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acyclovir</td>
<td>400 mg twice a day</td>
<td>[I¹]</td>
<td>Yes</td>
</tr>
<tr>
<td>Valacyclovir hydrochloride</td>
<td>500 mg once a day</td>
<td>[I¹]</td>
<td>Yes</td>
</tr>
<tr>
<td>Famciclovir</td>
<td>500 mg twice a day</td>
<td>[I¹]</td>
<td>Yes</td>
</tr>
</tbody>
</table>

Abbreviations: CDC, Centers for Disease Control and Prevention; FDA, Food and Drug Administration. Human immunodeficiency virus–positive patients.
Intermittent Suppressive Therapy

When recurrences can be anticipated, IST can be initiated to prevent oral and genital herpes outbreaks. Oral antiviral drugs are used for short periods when known precipitating factors might otherwise trigger reactivation of disease. Anticipatory treatment is also recommended in situations where decreasing viral shedding decreases the likelihood of infecting seronegative individuals with the virus.

Common stressors that can initiate herpes recurrences include ultraviolet radiation, physical trauma or surgery, emotional stress, menstrual cycles, and hormonal factors. Clinical trials with topical (5% cream applied 5 times a day) and systemic (200 mg twice a day) acyclovir regimens have been proven effective in preventing sunlight-induced episodes of recurrent labial herpes. Oral acyclovir and placebo groups experienced similar frequencies of labial herpes recurrences during the first few days of sun exposure. Significant reduction in number of recurrences became evident on the fifth day of treatment in the oral acyclovir group and during the 4-day follow-up period in the topical acyclovir group.

Prophylactic treatment has also been shown to significantly decrease recurrence rates of labial herpes in patients undergoing dental procedures. A study of patients prophylactically treated with valacyclovir before dental procedures found that clinical lesions appeared in 11.3% of test group patients and 20.6% of patients receiving a placebo, illustrating a 46% reduction in the number of clinically evident lesions.

Intermittent suppressive therapy is also useful in small populations to decrease the risk of virus transmission to uninfected individuals. Although only 5% to 10% of reproductive-age women have a history of genital herpes lesions, 25% to 30% are seropositive for HSV type 2. Roughly 5% to 10% of pregnant women experience a symptomatic herpes infection at some point during pregnancy. If such a recurrence occurs during the peripartum period, especially if the infection is primary, consequences to the fetus can be devastating. These cases are routinely managed with cesarean section, but anticipatory treatment offers a more practical solution. Decision making can be guided with vaginal herpes cultures at regular intervals during the third trimester. Acyclovir initiated at 36 weeks’ gestation has significantly reduced the rate of HSV recurrence in several small studies. Trials have also proven valacyclovir effective in significantly decreasing clinical and asymptomatic viral shedding.

Intermittent suppressive therapy can also prevent viral transmission to uninfected athletes competing in wrestling (herpes gladiatorum) and rugby. A 2003 study of prophylactic valacyclovir was conducted at a month-long wrestling camp. Two diagnostically confirmed outbreaks were reported compared with 15 to 20 outbreaks in 2002 and 57 outbreaks in 2001, conferring 78% and 87% decreases in outbreaks, respectively.

Dosing recommendations for IST of oral and genital herpes infections have not yet been published, but it has been our experience that using the same dosing during periods when outbreaks are anticipated as those used in long-term suppressive therapy is quite effective (Table 5 and Table 6).

Accepted for Publication: December 18, 2008.

Correspondence: Robert T. Brodell, MD, Brodell Medical Inc, 2660 E Market St, Warren, OH 44483 (rtb@neoucom.edu).

Author Contributions: Drs Cernik and Brodell had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Gallina and Brodell. Acquisition of data: Cernik. Analysis and interpretation of data: Cernik and Brodell. Drafting of the manuscript: Cernik and Brodell. Critical revision of the manuscript for important intellectual content: Gallina and Brodell. Study supervision: Gallina and Brodell.

Financial Disclosure: Dr Brodell has received honoraria for speaking engagements from Novartis (manufacturer of Famvir) and GlaxoSmithKline (manufacturer of Valtrex and Zovirax).

REFERENCES


80. Ormrod D, Scott LJ, Perry CM. Valacyclovir: a review of its long term utility in the management of genital herpes simplex virus and cyto